Jagsonpal Pharmaceuticals Complete Financial Statements
JAGSNPHARM • Review detailed financials to uncover trends, confirm thesis & journal trades
11 Years of Data
2025 - 2015
Complete Financial Data Export
Export complete financial statements for Jagsonpal Pharmaceuticals (JAGSNPHARM).
Downloads include all available records across all periods.
For market performance, see the
JAGSNPHARM stock price today
.
Profitability Ratios
Net Profit Margin
19.86%
2025 data
EBITDA Margin
21.30%
2025 data
Operating Margin
19.00%
2025 data
Return on Assets
19.78%
2025 data
Return on Equity
22.92%
2025 data
Balance Sheet Ratios
Current Ratio
13.42
2025 data
Debt to Equity
1.16
2025 data
Equity Ratio
86.33%
2025 data
Asset Turnover
1.00
2025 data
Year-over-Year Growth Analysis
Comparing March 2025 vs Period
Revenue Growth
+14.4%
Year-over-Year
Net Profit Growth
+12.7%
Year-over-Year
EBITDA Growth
+50.8%
Year-over-Year
Expense Growth
+4.6%
Year-over-Year
Assets Growth
+28.1%
Year-over-Year
Equity Growth
+28.3%
Year-over-Year
Liabilities Growth
+28.1%
Year-over-Year
Operating Cash Flow Growth
+57.1%
Year-over-Year
Investing Cash Flow Growth
-80.0%
Year-over-Year
Financing Cash Flow Growth
-33.3%
Year-over-Year
Income Statement
Periods
₹ Crores
| Particulars | None | March 2025 | March 2024 | March 2023 | March 2022 | March 2021 | March 2020 | March 2019 | March 2018 | March 2017 | March 2016 | March 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 317 | 277 | 218 | 242 | 221 | 192 | 161 | 168 | 127 | 144 | 144 | 138 |
| Expenses | 228 | 218 | 186 | 203 | 193 | 169 | 150 | 158 | 138 | 138 | 132 | 129 |
| EBITDA | 89 | 59 | 32 | 40 | 29 | 24 | 11 | 11 | -11 | 6 | 13 | 9 |
| Operating Profit Margin % | 19.00% | 19.00% | 11.00% | 14.00% | 12.00% | 10.00% | 5.00% | 6.00% | -9.00% | 4.00% | 8.00% | 6.00% |
| Depreciation | 9 | 8 | 2 | 1 | 2 | 1 | 1 | 1 | 0 | 2 | 3 | 3 |
| Interest | 1 | 1 | 1 | 0 | 0 | 1 | 1 | 1 | 1 | 3 | 5 | 5 |
| Profit Before Tax | 79 | 70 | 30 | 35 | 27 | 22 | 9 | 9 | -12 | 14 | 4 | 2 |
| Tax | 16 | 15 | 7 | 8 | 8 | 5 | 2 | 2 | 0 | 3 | 1 | 1 |
| Net Profit | 62 | 55 | 23 | 27 | 19 | 17 | 8 | 7 | -12 | 12 | 3 | 1 |
| Earnings Per Share (₹) | 9.20 | 8.26 | 8.49 | 10.20 | 7.20 | 6.51 | 3.00 | 2.75 | -4.41 | 4.53 | 1.24 | 0.45 |
Related Pages for Jagsonpal Pharmaceuticals
Additional stock information and data for JAGSNPHARM
Balance Sheet
Years
Annual Data
₹ Crores
| Particulars | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | |||||||||||
| Total Assets | 278 | 217 | 195 | 164 | 164 | 147 | 136 | 130 | 143 | 159 | 154 |
| Current Assets | 161 | 199 | 165 | 109 | 121 | 95 | 98 | 95 | 110 | 101 | 96 |
| Fixed Assets | 95 | 9 | 24 | 23 | 26 | 22 | 22 | 21 | 22 | 52 | 52 |
| Capital Work in Progress | 0 | 0 | 0 | 0 | 0 | 4 | 4 | 3 | 0 | 0 | 0 |
| Investments | 0 | 0 | 1 | 51 | 15 | 11 | 0 | 0 | 0 | 0 | 0 |
| Other Assets | 184 | 208 | 170 | 91 | 123 | 109 | 110 | 106 | 121 | 108 | 102 |
| LIABILITIES | |||||||||||
| Total Liabilities | 278 | 217 | 195 | 164 | 164 | 147 | 136 | 130 | 143 | 159 | 154 |
| Current Liabilities | 12 | 11 | 9 | 5 | 2 | 3 | 3 | 3 | 3 | 4 | 4 |
| Non-Current Liabilities | |||||||||||
| SHAREHOLDERS' EQUITY | |||||||||||
| Total Equity | 240 | 187 | 159 | 133 | 122 | 111 | 105 | 98 | 110 | 98 | 95 |
| Share Capital | 13 | 13 | 13 | 13 | 13 | 13 | 13 | 13 | 13 | 13 | 13 |
| Reserves & Surplus | 226 | 174 | 146 | 120 | 109 | 98 | 91 | 85 | 97 | 85 | 82 |
Cash Flow Statement
Periods
₹ Crores
| Particulars | March 2025 | March 2024 | March 2023 | March 2022 | March 2021 | March 2020 | March 2019 | March 2018 | March 2017 | March 2016 | March 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Activities | 55 | 35 | 47 | 7 | 28 | 11 | 31 | -2 | -3 | 9 | 4 |
| Investing Activities | -45 | -25 | -58 | -26 | -2 | -11 | -1 | -3 | 41 | -2 | -1 |
| Financing Activities | -12 | -9 | -1 | -18 | -7 | -1 | -6 | -1 | -34 | -6 | -1 |
| Net Cash Flow | -2 | 2 | -12 | -36 | 19 | -1 | 24 | -6 | 5 | 1 | 2 |